Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.50 |
| ▸ | PLAU | P00749 | 4/20 | 0.49 |
| ▸ | F9 | P00740 | 1/20 | 0.49 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.49 |
| ▸ | PLG | P00747 | 2/20 | 0.49 |
| ▸ | F12 | P00748 | 1/20 | 0.49 |
| ▸ | F11 | P03951 | 1/20 | 0.49 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.49 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.49 |
| ▸ | KMO | O15229 | 2/20 | 0.49 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.46 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 1/20 | 0.46 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
| ▸ | ATR | Q13535 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27201518 | 0.84 | CA12 (0.51) | PLAUERN1AXL | |
| SCHEMBL6978513 | 0.84 | PLAU (0.63) | PLAUF12 | |
| SCHEMBL27201415 | 0.81 | ERN1 (0.52) | ERN1ATR | |
| SCHEMBL30885245 | 0.81 | ERN1 (0.52) | ERN1ATR | |
| SCHEMBL27201480 | 0.79 | L3MBTL1 (0.56) | MAP4K4ERN1ATR | |
| SCHEMBL30885229 | 0.79 | L3MBTL1 (0.56) | MAP4K4ERN1ATR | |
| SCHEMBL14568169 | 0.78 | MAP4K4 (0.68) | MAP4K4LIMK1 | |
| SCHEMBL27201434 | 0.77 | ATR (0.57) | MAP4K4AXLATR | |
| SCHEMBL27990709 | 0.77 | MAP4K4 (0.60) | MAP4K4PLAUPLGF12F11 | |
| Trifluoroacetic Acid SCHEMBL6978086 | 0.76 | PLAU (0.55) | MAP4K4PLAUF12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2024073502-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | GID4, MDM2, XIAP | MAP4K4 1878/4885PLAU 4362/4885F9 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.